

05/01/98
JCSSES U.S. PRO

Attorney Docket No. 205.5
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischofberger et al.

Serial No.: 08/653,034

Group No.: 1614

Filed: May 24, 1996

Examiner: K. Weddington

For: NOVEL COMPOUNDS AND METHODS FOR SYNTHESIS AND THERAPY

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date: April 29, 1998

Robin Torres
(Signature of person mailing paper)



Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 35,071

Tel. No.: (650) 572-6569

SIGNATURE OF ATTORNEY

Mark L. Bosse

Type or print name of attorney

Gilead Sciences, Inc.

333 Lakeside Drive

P.O. Address

Foster City, CA 94404

GP1614 \$

05/01/98
3555 U.S. PRO

Attorney Docket No. 205.5
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischofberger et al.

Serial No.: 08/653,034

Group No.: 1614

Filed: May 24, 1996

Examiner: K. Weddington

For: NOVEL COMPOUNDS AND METHODS FOR SYNTHESIS AND THERAPY
RECEIVED

Assistant Commissioner for Patents

Washington, D.C. 20231

MAY - 6 1998

ATTENTION: GROUP DIRECTOR

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT AFTER
MAILING DATE OF FINAL ACTION OR NOTICE OF ALLOWANCE
BUT BEFORE PAYMENT OF ISSUE FEE (37 CFR 1.97 (d))**

**TIME OF TRANSMITTAL OF ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed *after* a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first, but before, or simultaneously with the payment of the issue fee.

CERTIFICATION, PETITION AND FEE

2. In accordance with the requirements of 37 CFR 1.97 (d):

- A. Accompanying this transmittal is a certification as specified in 37 CFR 1.97 (e).
- B. Applicant hereby petitions for the consideration of the accompanying information disclosure statement. 37 CFR 1.97 (d) (ii).
- C. Applicant submits the petition fee set forth in § 1.17 (i) (1). (\$130.00).

FEE DUE

3. Petition fee due (§ 1.17 (i) (1)) (\$130.00)

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date: April 29, 1998

Robin Torres
(Signature of person mailing paper)

05/04/1998 RMW:RFB
01 FC:122
00000002 071256 08653034

METHOD OF PAYMENT OF FEE

4.

☐ attached is check for \$130.00.

☒ charge Account No. 07-1250 \$130.00.

A duplicate of this petition is attached.

If any additional petition fees are due, please charge Account No. 07-1250.

Reg. No. 35,071



SIGNATURE OF ATTORNEY

Tel. No.: (650) 572-6569

Mark L. Bosse
Type or print name of attorney

Gilead Sciences, Inc.
333 Lakeside Drive
P.O. Address

Foster City, CA 94404

1555 U.S. PTO
05/01/98

Attorney Docket No. 205.5
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischofberger et al.

Serial No.: 08/653,034

Group No.: 1614

Filed: May 24, 1996

Examiner: K. Weddington

For: NOVEL COMPOUNDS AND METHODS FOR SYNTHESIS AND THERAPY

Assistant Commissioner for Patents

Washington, D.C. 20231

**CERTIFICATION FOR INFORMATION DISCLOSURE STATEMENT
(37 CFR 1.97 (e))**

**IDENTIFICATION OF INFORMATION DISCLOSURE
STATEMENT FOR WHICH THIS CERTIFICATION
IS BEING MADE**

1. This certification is being made for the Information Disclosure Statement

☒ accompanying this certification

☐ filed _____
(date)

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: April 29, 1998

Robin Torres
(Type or print name of person mailing paper)
Robin Torres
(Signature of person mailing paper)

CERTIFICATION

2. I, the person(s) signing below certify

- ☒ that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. 37 CFR 1.97 (e) (1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in § 1.56 (c) more than three months prior to the filing of the statement. 37 CFR 1.97 (e) (2).

IDENTIFICATION OF PERSON(S) MAKING THIS CERTIFICATION

3. The person making this certification is the attorney who signs below on the basis of the information in the attorney's file

Reg. No. 35,071

Tel. No.: (650) 572-6569



SIGNATURE OF ATTORNEY

Mark L. Bosse

Type or print name of attorney

Gilead Sciences, Inc.

333 Lakeside Drive

P.O. Address

Foster City, CA 94404